22 May 2013
Keywords: aeterna, zentaris, loss, up, costs, canadian, drugmaker
Article | 30 March 2009
Canadian drugmaker AEterna Zentaris' 2008 loss jumped 85% on decreased turnover and increased R&D expenses for its lead candidate cetrorelix.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 March 2009
21 May 2013
© 2013 thepharmaletter.com